Fibrolamellar hepatocellular carcinoma: An immunohistochemical comparison with conventional hepatocellular carcinoma

International Journal of Surgical Pathology

Volumn 18, Issue 5, 2010, Pages 313-318

  Abdul Al, Hala M ^a,b   Guanghua Wang, ^a   Makhlouf, Hala R ^a   Goodman, Zachary D ^a  

^a ARMED FORCES INSTITUTE OF PATHOLOGY   (United States)

^b AIN SHAMS UNIVERSITY   (Egypt)

Author keywords

CK7; fibrolamellar carcinoma; glypican 3; hepatocellular carcinoma; immunohistochemistry; survivin

Indexed keywords

CD34 ANTIBODY; CYTOKERATIN 19; CYTOKERATIN 7; GLYPICAN 3; SURVIVIN;

ANTIGEN EXPRESSION; ARTICLE; CONTROLLED STUDY; FIBROLAMELLAR HEPATOCELLULAR CARCINOMA; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LIVER CELL CARCINOMA; LIVER SINUSOID; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANTIGENS, CD34; CARCINOMA, HEPATOCELLULAR; GLYPICANS; HUMANS; IMMUNOENZYME TECHNIQUES; KERATIN-19; KERATIN-7; KERATINS; LIVER NEOPLASMS; MICROTUBULE-ASSOCIATED PROTEINS; NEOPLASM PROTEINS; TUMOR MARKERS, BIOLOGICAL;

EID: 78549286388     PISSN: 10668969     EISSN: 19402465     Source Type: Journal    
DOI: 10.1177/1066896910364229     Document Type: Article

References (36)

1. Ishak KG, Goodman ZD, Stocker JT, eds. Tumors of the Liver and Intrahepatic Bile Ducts. Washington, DC: Armed Forces Institute of Pathology ; 2001. Atlas of Tumor Pathology, Third Series, Fascicle 31.
2. Torbenson M. Review of the clinicopathologic features of fibrolamellar carcinoma. Adv Anat Pathol. 2007 ; 14: 217-223.
3. Bosch FX, Ribes J., Diaz M., Cleries R. Primary liver cancer: worldwide incidence and trends. Gastroenterology. 2004 ; 127: S5 - S16.
4. El-Sarag HB Hepatocellular carcinoma: recent trends in the United States. Gastroenterology. 2004 ; 127: S27 - S34.
5. Berman MA, Burnham JA, Sheahan DG Fibrolamellar carcinoma of the liver: an immunohistochemical study of nineteen cases and a review of the literature. Human Pathol. 1988 ; 19: 784-794.
6. Scoazec JY, Flejou JF, Dg'Errico A., et al. Fibrolamellar carcinoma of the liver: composition of the extracellular matrix and expression of cell-matrix and cell-cell adhesion molecules. Hepatology. 1996 ; 24: 1128-1136.
7. Schoedel KE, Tyner VZ, Kim TH, Michalopoulos GK, Mars WM HGF, MET, and matrix-related proteases in hepatocellular carcinoma, fibrolamellar variant, cirrhotic and normal liver. Mod Pathol. 2003 ; 16: 14-21.
8. Klein WM, Molmenti EP, Colombani PM, et al. Primary liver carcinoma arising in people younger than 30 years. Am J Clin Pathol. 2005 ; 124: 512-518.
9. Kakar S., Burgart LJ, Batts KP, Garcia J., Jain D., Ferrell LD Clinicopathologic features and survival in fibrolamellar carcinoma: comparison with conventional hepatocellular carcinoma with and without cirrhosis. Mod Pathol. 2005 ; 8: 1417-1423.
10. Peters MG, Farias E., Colombo L., Filmus J., Puricelli L., Bal de Kier Joffe E. Inhibition of invasion and metastasis by glypican-3 in a syngeneic breast cancer model. Breast Cancer Res Treat. 2003 ; 80: 221-232.
11. Nakatsura T., Kageshita T., Ito S., et al. Identification of glypican-3 as a novel tumor marker for melanoma. Clin Cancer Res. 2004 ; 10: 6612-6621.
12. Zynger DL, Dimov ND, Luan C., Teh BT, Yang XJ Glypican 3: a novel marker in testicular germ cell tumors. Am J Surg Pathol. 2006 ; 30: 1570-1575.
13. Capurro M., Wanless IR, Sherman M., et al. Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma. Gastroenterology. 2003 ; 125: 89-97.
14. Yamauchi N., Watanabe A., Hishinuma M., et al. The glypican 3 oncofetal protein is a promising diagnostic marker for hepatocellular carcinoma. Mod Pathol. 2005 ; 18: 1591-1598.
15. Libbrecht L., Severi T., Cassiman D., et al. Glypican-3 expression distinguishes small hepatocellular carcinomas from cirrhosis, dysplastic nodules, and focal nodular hyperplasia-like nodules. Am J Surg Pathol. 2006 ; 30: 1405-1411
16. Wang XY, Degos F., Dubois S., et al. Glypican-3 expression in hepatocellular tumors: diagnostic value for preneoplastic lesions and hepatocellular carcinomas. Hum Pathol. 2006 ; 37: 1435-1441.
17. Llovet JM, Chen Y., Wurmbach E., et al. A molecular signature to discriminate dysplastic nodules from early hepatocellular carcinoma in HCV cirrhosis. Gastroenterology. 2006 ; 131: 1758-1767.
18. Di Tommaso L., Franchi G., Park YN, et al. Diagnostic value of HSP70, glypican 3, and glutamine synthetase in hepatocellular nodules in cirrhosis. Hepatology. 2007 ; 45: 725-734.
19. LaCasse EC, Baird S., Korneluk RG, MacKenzie AE The inhibitors of apoptosis (IAPs) and their emerging role in cancer. Oncogene. 1998 ; 17: 3247-3259.
20. Deveraux QL, Reed JC IAP family proteins-suppressors of apoptosis. Genes Dev. 1999 ; 13: 239-252.
21. Ito T., Shiraki K., Sugimoto K., et al. Survivin promotes cell proliferation in human hepatocellular carcinoma. Hepatology. 2000 ; 31: 1080-1085.
22. Moon WS, Tarnawski AS Nuclear translocation of surviving in hepatocellular carcinoma: a key to cancer cell growth ? Hum Pathol. 2003 ; 34: 1119-1126.
23. Fields A., Cotsonis G., Sexton D., Santoianni R., Cohen C. Survivin expression in hepatocellular carcinoma: correlation with proliferation, prognostic parameters, and outcome. Mod Pathol. 2004 ; 17: 1378-1385.
24. Hsu SM, Raine L., Fanger H. Use of avidin-biotin-perioxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabelled antibody procedures. J Histochem Cytochem. 1981 ; 29: 577-580.
25. Filmus J., Selleck SB Glypicans: proteoglycans with a surprise. J Clin Invest. 2001 ; 108: 497-501.
26. Grozdanov PN, Yovchev MI, Dabeva MD The oncofetal protein glypican-3 is a novel marker of hepatic progenitor/ oval cells. Lab Invest. 2006 ; 86: 1272-1284.
27. Moon WS, Tarnawski AS Nuclear translocation of surviving in hepatocellular carcinoma: a key to cancer cell growth ? Hum Pathol. 2003 ; 34: 1119-1126.
28. Fields A., Cotsonis G., Sexton D., Santoianni R., Cohen C. Survivin expression in hepatocellular carcinoma: correlation with proliferation, prognostic parameters, and outcome. Mod Pathol. 2004 ; 17: 1378-1385.
29. Wu PC, Fang JW, Lau VK, Lai CL, Lo CK, Lau JY Classification of hepatocellular carcinoma according to hepatocellular and biliary differentiation markers: clinical and biological implications. Am J Pathol. 1996 ; 149: 1167-1175.
30. Durnez A., Verslype C., Nevens F., et al. The clinicopathological and prognostic relevance of cytokeratin 7 and 19 expression in hepatocellular carcinoma: a possible progenitor cell origin. Histopathology. 2006 ; 49: 138-151.
31. Van Eyken P., Sciot R., Brock P., Casteels-Van Daele M., Ramaekers FCS, Desmet VJ Abundant expression of cytokeratin 7 in fibrolamellar carcinoma of the liver. Histopathology. 1990 ; 17: 101-107.
32. Van Eyken P., Sciot R., Desmet VJ A cytokeratin immunohistochemical study of cholestatic liver disease: evidence that hepatocytes can express "bile duct-type" cytokeratins. Histopathology. 1989 ; 15: 125-135.
33. Dhillon AP, Colombari R., Savage K., Scheuer PJ An immunohistochemical study of the blood vessels within primary hepatocellular tumours. Liver. 1992 ; 12: 311-318.
34. Ruck P., Xiao JC, Kaiserling E. Immunoreactivity of sinusoids in hepatocellular carcinoma: an immunohistochemical study using lectin UEA-1 and antibodies against endothelial markers, including CD34. Arch Pathol Lab Med. 1995 ; 119: 173-178.
35. Tanigawa N., Lu C., Mitsui T., Miura S. Quantification of sinusoidal-like vessels in hepatocellular carcinoma: its clinical and prognostic significance. Hepatology. 1997 ; 26: 1216-1223.
36. Kimura H., Nakajima T., Kagawa K., et al. Angiogenesis in hepatocellular carcinoma as evaluated by CD34 immunohistochemistry. Liver. 1998 ; 18: 14-19.